Literature DB >> 29559516

Immunomodulatory Effects of Momordica charantia Extract in the Prevention of Oral Cancer.

Chinthalapally V Rao1.   

Abstract

In recent times, bitter melon extract (BME) has gained significant attention for its anticancer efficacy against various malignancies. In this issue, Sur and colleagues show that BME prevents the development of 4-nitronitroquinoline 1-oxide-induced oral dysplasia and squamous cell carcinoma (SCC) in an immunocompetent mouse model. Importantly, gene ontology and pathway analyses revealed an elevated expression of s100a9, IL23a, IL1β, and PDCD1/PD1 of immune system during oral cancer development, which was significantly suppressed by BME. Overall, this study demonstrates the potential clinical benefits of BME in preventing and delaying the progression of oral dysplasia to SCC. Cancer Prev Res; 11(4); 185-6. ©2018 AACRSee related article by Sur et al., p. 191. ©2018 American Association for Cancer Research.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 29559516     DOI: 10.1158/1940-6207.CAPR-17-0379

Source DB:  PubMed          Journal:  Cancer Prev Res (Phila)        ISSN: 1940-6215


  4 in total

1.  Bioactivity-Guided Isolation of Neuritogenic Factor from the Seeds of the Gac Plant (Momordica cochinchinensis).

Authors:  E Mazzio; R Badisa; S Eyunni; S Ablordeppey; B George; K F A Soliman
Journal:  Evid Based Complement Alternat Med       Date:  2018-05-31       Impact factor: 2.629

2.  Inhibition of the key metabolic pathways, glycolysis and lipogenesis, of oral cancer by bitter melon extract.

Authors:  Subhayan Sur; Hiroshi Nakanishi; Colin Flaveny; Joseph E Ippolito; Jane McHowat; David A Ford; Ratna B Ray
Journal:  Cell Commun Signal       Date:  2019-10-21       Impact factor: 5.712

Review 3.  The Effect of Momordica charantia in the Treatment of Diabetes Mellitus: A Review.

Authors:  Zhuo Liu; Jing Gong; Wenya Huang; Fuer Lu; Hui Dong
Journal:  Evid Based Complement Alternat Med       Date:  2021-01-16       Impact factor: 2.629

4.  Long non-coding RNA ELDR enhances oral cancer growth by promoting ILF3-cyclin E1 signaling.

Authors:  Subhayan Sur; Hiroshi Nakanishi; Robert Steele; Dapeng Zhang; Mark A Varvares; Ratna B Ray
Journal:  EMBO Rep       Date:  2020-10-12       Impact factor: 9.071

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.